Dupilumab and Sanofi's COPD drugs show promising results in clinical trials.

Sanofi and Regeneron's anti-inflammatory drug Dupixent showed a 30% reduction in acute exacerbations of chronic obstructive pulmonary disease (COPD) in a one-year clinical trial. The benefits of the drug were seen within two weeks and sustained throughout the trial. Sanofi is discussing with regulators whether the results are substantial enough to support a regulatory review or whether another ongoing trial is required. Dupixent is approved to treat conditions including asthma and eczema and is expected to generate up to €13bn ($14.2bn) in sales in its best year.